Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511548-19-00

Acronym

RMC-6291-001

Enrollment

104

Registered

2024-04-01

Start date

2022-12-13

Completion date

Unknown

Last updated

2025-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Solid Tumor, Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Czechia, France, Italy, Poland, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026